RBM10 and neoplasm: Following 2 months of neoadjuvant osimertinib treatment, we confirmed low tumor cell RBM10 expression and observed radiographic SD, with 80% tumor cell viability in the osimertinib-treated, resected tumor specimen upon clinical pathology assessment (Figure 4D).